Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Aug-11-26 | Downgrade | Evercore ISI | Outperform → In-line | $5 |
| Aug-11-26 | Downgrade | Chardan Capital Markets | Buy → Neutral | $5 |
| Jul-28-26 | Initiated | Canaccord Genuity | Buy | $35 |
| Jul-22-26 | Initiated | Evercore ISI | Outperform | $39 |
| Jun-22-26 | Initiated | Chardan Capital Markets | Buy | $27 |
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight | $35 |
| Sep-08-25 | Initiated | Piper Sandler | Overweight | $20 |
| Oct-24-24 | Initiated | Leerink Partners | Outperform | $16 |
| Oct-14-24 | Initiated | Guggenheim | Buy | $16 |
| Sep-30-24 | Initiated | William Blair | Outperform | |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy | |
| Dec-16-14 | Initiated | MLV & Co | Buy | $7 |
| Nov-18-14 | Initiated | WallachBeth | Buy | $12 |